ZYBT Zhengye Biotechnology Holding Ltd Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1975641
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · CNY | FY20232023-12-31 · CNY | FY20222022-12-31 · CNY |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $16.64M | 186.36M | 211.65M | 260.27M |
| Cost of revenue | $13.23M | 95.06M | 94.14M | 112.39M |
| Gross profit | $3.41M | 91.30M | 117.51M | 147.88M |
| R&D expense | $2.58M | 12.79M | 11.90M | 13.42M |
| SG&A expense | $4.43M | 22.57M | 23.59M | 24.32M |
| Operating income | -$10.08M | 16.44M | 44.99M | 65.83M |
| Interest expense | $486,000 | 4.04M | 4.42M | 2.84M |
| Pretax income | -$10.28M | 14.39M | 43.76M | 63.91M |
| Income tax | $1.59M | 924,000 | 6.25M | 8.17M |
| Net income | -$9.98M | 11.31M | 31.46M | 46.73M |
| EBITDA | -$6.38M | 40.60M | 68.90M | 84.63M |
| EPS (basic) | — | 0.25 | 0.69 | 1.02 |
| EPS (diluted) | — | 0.25 | 0.69 | 1.02 |
| Weighted avg. shares (diluted) | 47.35M | 45.67M | 45.67M | 45.67M |
| Balance sheet | ||||
| Cash & equivalents | $7.20M | 18.61M | 27.19M | 9.75M |
| Short-term investments | $223,000 | 1.43M | 1.22M | — |
| Receivables | $2.64M | 59.56M | 74.17M | — |
| Inventory | $5.60M | 58.22M | 58.30M | — |
| Current assets | $19.65M | 177.57M | 189.24M | — |
| PP&E, net | $33.86M | 255.16M | 263.25M | — |
| Intangibles | $6.73M | 14.85M | 16.30M | — |
| Total assets | $62.41M | 493.25M | 499.89M | — |
| Current liabilities | $17.23M | 135.91M | 150.23M | — |
| Short-term debt | $100,000 | 7.19M | 79.86M | — |
| Long-term debt | $1.37M | 4.80M | 9.99M | — |
| Total debt | $1.47M | 11.99M | 89.85M | — |
| Total liabilities | $18.56M | 140.71M | 160.62M | — |
| Shareholders' equity | $35.72M | 283.96M | 272.85M | 356.87M |
| Net debt | -$5.73M | -6.62M | 62.66M | — |
| Shares outstanding | — | 45.67M | 45.67M | — |
| Cash flow statement | ||||
| Operating cash flow | $1.91M | 41.05M | 48.18M | 17.34M |
| Capital expenditure | $144,000 | 13.59M | 7.40M | 27.33M |
| Free cash flow | $1.77M | 27.46M | 40.79M | -9.99M |
| Investing cash flow | -$1.81M | -27.66M | -11.77M | -27.33M |
| Financing cash flow | $4.62M | -22.13M | -18.98M | 13.46M |
| Depreciation & amortization | $3.70M | 24.16M | 23.91M | 18.80M |
| Dividends paid | — | 16.02M | 39.45M | 21.43M |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.